Amneal Pharmaceuticals, Inc. quarterly report, Q1 FY2022

Business context and reporting period

Amneal Pharmaceuticals, Inc. filed this unaudited Form 10-Q for the three months ended March 31, 2022. The company develops, manufactures, markets and distributes generic and specialty pharmaceuticals, and operates through Generics, Specialty and AvKARE segments. Unless otherwise stated, amounts below are in millions of dollars.

Key financial metrics

At March 31, 2022, current assets were $1,389.7 and current liabilities were $602.0. Debt carrying value was approximately $2,703.2, comprising current and long-term debt; the company reported $446.9 of available revolving-credit capacity. Cash, cash equivalents and restricted cash totaled $216.5. Cash paid for interest during the quarter was $27.3.

Segment revenue was $317.7 for Generics, $85.1 for Specialty and $94.8 for AvKARE. Segment operating income was $45.3, $7.1 and $1.2, respectively.

Material changes versus the prior comparable period

• Revenue rose 1% overall. Generics increased 2%, supported by new product launches and volume, partly offset by price erosion. AvKARE increased 12%, driven by distribution. Specialty fell 11%, primarily reflecting Zomig nasal spray loss of exclusivity and declines in other non-promoted products.
• Cost of goods sold increased 7%, outpacing revenue growth; gross margin fell four percentage points to 35%. Management cited higher volume and reduced operating-efficiency benefits.
• SG&A increased to $98.7 from $90.7, including a $5.0 biosimilar regulatory-approval expense. R&D rose to $52.8 from $48.2.
• Operating income roughly halved and the company moved from net income to a net loss. Other expense increased to $33.2, including an unfavorable foreign-exchange comparison, partly offset by lower interest expense.
• Operating cash flow declined to $120.3. Investing cash outflow rose to $97.4, largely due to the $84.7 Saol acquisition payment; financing cash outflow was $61.6, including deferred acquisition consideration payments.

Outlook, management commentary, risks and unusual items

• Management estimated 2022 capital expenditures of $75–$85 and an approximately $20 inflationary impact for 2022; higher material, transportation and labor costs could exceed that estimate. The filing gives no specific revenue or earnings guidance.
• Management said available liquidity sources were expected to fund planned operations and obligations for at least the next 12 months, while noting dependence on demand, economic conditions and the COVID-19 pandemic.
• The Saol baclofen-franchise acquisition closed February 9 for $84.7 cash plus estimated contingent royalties of $8.8. It contributed $2.9 of revenue and a $0.1 operating loss through quarter-end. The FDA approved the company’s bevacizumab biosimilar on April 13, after quarter-end; a $10 milestone payment was incurred in Q2.
• The company was eligible for up to approximately $132.3 in Indian government pharmaceutical incentives over a maximum six-year period, subject to investment and sales targets; recognition was expected to begin in Q2 2022.
• Legal matters remain a significant uncertainty. Recorded legal liabilities were $59.7 at March 31, including $37.0 for securities class actions covered by insurance. The filing describes ongoing opioid, generic-drug pricing, antitrust and other proceedings; outcomes and potential losses are generally not estimable. A $1.2 charge was recorded for a tentative wage-case settlement, and the company recorded a $2.3 net legal credit, including a $4.0 insurance recovery.
• The tax receivable agreement’s contingent liability was estimated at approximately $206.3 but was not recognized because utilization of the related tax assets was not considered more likely than not. The agreement generally requires payment of 85% of applicable tax savings and may create substantial liquidity demands.
• Three customers each represented at least 10% of quarterly revenue; together they accounted for 60%. Three customers also represented 83% of trade receivables at quarter-end. The company identified competition and price erosion, supplier and supply-chain dependence, indebtedness and interest-rate exposure, inflation, COVID-related disruption, and regulatory and litigation risks.

Important facts for investors to verify

1. Whether new product launches and the Saol franchise can offset generic price erosion and Specialty product declines, and whether gross margins recover.
2. Debt terms, variable-rate exposure, interest-rate swap coverage, scheduled repayments and refinancing capacity, given substantial debt and lower cash balances.
3. Progress toward the stated 2022 capex and inflation assumptions, and the conditions and timing for any Indian government incentive payments.
4. Developments in major litigation, insurance coverage and recoveries, and any changes to recorded legal liabilities or potential losses.
5. Tax-asset realizability and potential tax receivable agreement payments, including the consequences of future unit exchanges or a change of control.
6. Customer concentration, receivables collection, inventory growth and supply continuity; also confirm post-quarter developments, including the biosimilar approval and related milestone payment.